Comparison of high-dose IVIG and rituximab versus rituximab as a preemptive therapy for de novo donor-specific antibodies in kidney transplant patients

De novo donor-specific antibody (dnDSA) is associated with a higher risk of kidney graft failure. However, it is unknown whether preemptive treatment of subclinical dnDSA is beneficial. Here, we assessed the efficacy of high-dose intravenous immunoglobulin (IVIG) and rituximab combination therapy fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Hyung Woo, Lee, Juhan, Heo, Seok-Jae, Kim, Beom Seok, Huh, Kyu Ha, Yang, Jaeseok
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10175554/
https://www.ncbi.nlm.nih.gov/pubmed/37169835
http://dx.doi.org/10.1038/s41598-023-34804-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10175554/
https://www.ncbi.nlm.nih.gov/pubmed/37169835
http://dx.doi.org/10.1038/s41598-023-34804-6

Ejemplares similares